Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07312799
PHASE1
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
Sponsor: Addpharma Inc.
View on ClinicalTrials.gov
Summary
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
Official title: A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 in Healthy Adult Volunteers
Key Details
Gender
All
Age Range
19 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
41
Start Date
2026-01-27
Completion Date
2026-02-26
Last Updated
2025-12-31
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Treatment A(AD-2321)
AD-2321 Oral Tablet
DRUG
Treatment B(AD-2322)
AD-2322 Oral Tablet
DRUG
Treatment C(AD-2321+AD-2322)
AD-2321 Oral Tablet+AD-2322 Oral Tablet
Locations (1)
H+ Yangji Hospital
Seoul, South Korea